Trial Profile
Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 Mar 2012
Price :
$35
*
At a glance
- Drugs Octreotide (Primary) ; Methylprednisolone; Methylprednisolone
- Indications Cancer metastases; Solid tumours
- Focus Therapeutic Use
- Sponsors Novartis
- 01 Feb 2012 Results published in the Bulletin du Cancer.
- 13 Apr 2010 Planned end date added to 1 Sep 2008 as reported by ClinicalTrials.gov.
- 30 Mar 2010 Actual patient number (64) added as reported by ClinicalTrials.gov.